Jonas Bergquist

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Revision as of 20:02, September 19, 2020 by Notjusttired (talk | contribs) (long covid)
faculty.utah.edu

Jonas Bergquist, MD, PhD, is a Full Chair Professor in Analytical Chemistry and Neurochemistry at the Department of Chemistry at Uppsala University.[1] He also has served as an Associate Professor of Clinical Neuroscience at the Sahlgrenska University Hospital and Gothenburg University, Gothenburg, Sweden. In 1999, he became a Researcher in Uppsala University, Uppsala, Sweden. In 2005, he was appointed the Chaired Professor of Analytical Chemistry and Neurochemistry, heading the Bergquist group at the Department of Chemistry, Biomedical Centre, Uppsala University. Since 2011, he is an Adjunct Professor of Pathology at the University of Utah, Salt Lake City, US, and since 2015, a Professor of Precision Medicine, Binzhou Medical University, Yantai, China.[2]

Research interests: various neurodegenerative diseases such as Parkinson's, Alzheimer's, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS); his research "involves methods to measure substances that can act as biomarkers for early diagnosis and contribute to the understanding of what initiates the disease process... [and] measure not only the individual substances but also seek patterns and monitor how they change during illness,... [the Bergquist group's] specialty is the analysis of cerebrospinal fluid and its chemical composition."[2]

Dr Bergquist leads the Open Medicine Foundation's center in Uppsala, Sweden.[3]

Long covid[edit | edit source]

Professor Bergquist is principal investigator for the Open Medicine Foundation's COVID-19 and ME/CFS study, which was announced in May 2020.[4]

Working groups and committees[edit | edit source]

ME/CFS Collaborative Research Center at Stanford University[edit | edit source]

Member of the Working Group which offers their expertise and resources to the ME/CFS Collaborative Research Center at Stanford University.[5]

EUROMENE[edit | edit source]

Dr. Bergquist is a member of the Biomarkers Working Group of ME/CFS across Europe on behalf of the EUROMENE, a European Union COST Action CA15111 not-for-profit research organization committed to tackling the cause and treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.[6]

ME/CFS Common Data Element (CDE) Project[edit | edit source]

Member of the Biomarkers Working Group and Neurologic/Cognitive/CNS Imaging Working Group of the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Common Data Element (CDE) Project sponsored by the National Institute of Neurological Disorders and Stroke and the Centers for Disease Control and Prevention.[7]

2017 Ramsay Award[edit | edit source]

A team comprised of Dr. Bergquist and Dr. Jonas Blomberg of Uppsala University and Dr. Carl-Gerhard Gottfries and Dr. Olof Zachrisson of the Gottfries Clinic were awarded a 2017 Ramsay Award grant from the Solve ME/CFS Initiative for research into biomarkers for initiation (infection) and metabolic derangement in ME/CFS.[8]

Talks and interviews[edit | edit source]

Notable studies[edit | edit source]

  • 2020, Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients – A validation study in plasma and cerebrospinal fluid from two Swedish cohorts[9] - (Full text)
  • 2011, Distinct Cerebrospinal Fluid Proteomes Differentiate Post-Treatment Lyme Disease from Chronic Fatigue Syndrome[10] - (Full Text)

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 "ME/CFS Canadian Collaborative Team Conference program" (PDF). Retrieved March 6, 2019. Cite has empty unknown parameter: |dead-url= (help)
  2. 2.0 2.1 Johansson, Åke. "Jonas Bergquist - Uppsala University, Sweden". katalog.uu.se. Retrieved April 25, 2019.
  3. "Collaborative Center - Uppsala". Open Medicine Foundation. Retrieved August 15, 2020. Cite has empty unknown parameter: |dead-url= (help)
  4. Open Medicine Foundation (June 17, 2020). "COVID-19 and ME news flash from Uppsala". omf.org. Retrieved September 19, 2020. Cite has empty unknown parameter: |dead-url= (help)
  5. "OMF grants $1.2M to Ramp Up Collaborative Research Center at Stanford University". bos.etapestry.com. Retrieved April 25, 2019.
  6. "Action CA15111". COST. Retrieved April 25, 2019.
  7. "Complete Myalgic Encephalomyelitis/Chronic Fatigue Syndrome CDE Roster". NIH. Retrieved October 11, 2019. Cite has empty unknown parameter: |dead-url= (help)
  8. "2017 Ramsay Award Program Results". Solve ME/CFS Initiative. Retrieved April 25, 2019.
  9. Bynke, Annie; Julin, Per; Gottfries, Carl-Gerhard; Heidecke, Harald; Scheibenbogen, Carmen; Bergquist, Jonas (August 1, 2020). "Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients – A validation study in plasma and cerebrospinal fluid from two Swedish cohorts". Brain, Behavior, & Immunity - Health. 7: 100107. doi:10.1016/j.bbih.2020.100107. ISSN 2666-3546.
  10. Schutzer, Steven E; Angel, Thomas E.; Liu, Tao; Schepmoes, Athena A.; Clauss, Therese R.; Adkins, Joshua N.; Camp, David G.; Holland, Bart K.; Bergquist, Jonas; Coyle, Patricia K.; Smith, Richard D.; Fallon, Brian A.; Natelson, Benjamin (2011), "Distinct Cerebrospinal Fluid Proteomes Differentiate Post-Treatment Lyme Disease from Chronic Fatigue Syndrome", PLoS ONE, 6 (2), doi:10.1371/journal.pone.0017287